Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 59

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 59
---
 have harmful side effects or other undesirable characteristics that make them unmarketable or unlikely
to receive regulatory approval.

Research programs to pursue
the development of our drug candidates for additional indications and to identify new drug candidates and disease targets require substantial
technical, financial and human resources whether or not we ultimately are successful. Our research programs may initially show promise
in identifying potential indications and/or drug candidates, yet fail to yield results for clinical development for a number of reasons,
including but not limited to:

| ● | the research methodology used may not be successful in identifying 
 potential indications and/or drug candidates;                      |

| ● | potential drug candidates may, after further study, be shown                                                       
 to have harmful adverse effects or other characteristics that indicate they are unlikely to be effective drugs; or |

| ● | it may take greater human and financial resources to identify                                                                           
 additional therapeutic opportunities for our drug candidates or to develop suitable potential drug candidates through internal research 
 programs than we will possess, thereby limiting our ability to diversify and expand our drug portfolio.                                 |

Because we have limited financial
and managerial resources, we have chosen to focus at present on our three Lead Projects, which may ultimately prove to be unsuccessful.
As a result of this focus, we may forego or delay pursuit of opportunities with other drug candidates, or for other indications that later
prove to have greater commercial potential or a greater likelihood of success. Even if we determine to pursue alternative therapeutic
or diagnostic drug candidates, these other drug candidates or other potential programs may ultimately prove to be unsuccessful. In short,
our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.

Accordingly, there can be no
assurance that we will ever be able to develop suitable potential drug candidates through internal research programs. This could materially
adversely affect our future growth and prospects.

If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.

Although we obtained CTA/FDA
approval to initiate clinical trials for our Lead Projects, there can be no assurance, timely completion of clinical trials in accordance
with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who meet the trial criteria
and remain in the trial until its conclusion. We may experience difficulties enrolling and retaining appropriate patients in our clinical
trials for a variety of reasons, including but not limited to:

| ● | the size and nature of the patient population; |

| ● | patient